Hengrui Medicine

Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows

A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?

Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021

On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.

WIM2020: Insights on the Post-pandemic Outlook for the Healthcare Industry

The curtain came down on Dec 10 on the 'Healthtech Industry and COVID-19 Pandemic' Chapter at WIM 2020. Healthtech entrepreneurs and investors gathered to share insights on the outlook for the healthcare industry, covering topics like vaccination, AI healthcare, intelligent hardware, medical appliances and IVD.

CSPC Pharma’s Arthritis Painkiller Listed by China's Medical Agency

CSPC Pharmaceutical has seized the chance of entry into the third national centralized procurement and expects stable sales for the generic drug Celecoxib.

New Normal, New Policies: A Focus on Healthcare in Two Sessions 

The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.